406 results about "Asthma" patented technology

To provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue.SOLUTION: In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective in injuring or damaging tissue, nerves and nerve endings in order to relieve disease symptoms.SELECTED DRAWING: Figure 3B

The invention relates to the technical field of traditional Chinese medicine, in particular to a Mongolian medicine tea drink for relieving respiratory system abnormality and a preparation method and application thereof.The Mongolian medicine tea drink is prepared from rhododendron micranthum, pomegranate, amomum cardamomum, long pepper, cinnamon, safflower, agilawood, clove, myristica fragrans, fructus choerospondiatis, bistort rhizome, liquorice, tabasheer, radix aucklandiae, white raisin and crabs. The processed products of the Mongolian medicine components are weighed according to the formula dosage, then ground into coarse powder and bagged to prepare tea bags. The Mongolian medicine tea drink provided by the invention has the effects of moving Heli, relieving cough, reducing phlegm and diminishing swelling; the traditional Chinese medicine composition can be used for treating the symptoms such as' Bada dry Hiri 'dizziness, asthma, chronic bronchitis, indigestion disease, edema, edema and water tympanites.

Described herein are novel and improved antibodies that bind to thymic stromal lymphopoietin (TSLP) and methods of use thereof. In certain aspects, described herein are methods of inhibiting TSLP biological activity. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of TSLP. In certain aspects, described herein are methods of treating asthma by administering anti-TSLP antibodies.

The invention relates to the field of biological medicine, and discloses a method and system for analyzing cough sound by using disease characteristics to diagnose respiratory diseases, and the method comprises the steps: deploying a six-microphone annular array to achieve the precise positioning and triggering of a sound source; self-adaptive spectral subtraction and Wiener filtering cascade are adopted to enhance the audio; segmenting a cough segment based on energy envelope; fusing the Mel-cepstrum, the linear prediction residual error, the harmonic energy ratio and the transient zero-crossing rate to construct a pathological feature matrix; extracting local, medium-range and global time sequence features through a three-branch parallel convolutional network; inputting a disease specific classifier to discriminate asthma, pneumonia and laryngitis respectively, and applying a feature decoupling regular term to improve interpretability. The system correspondingly realizes the modularized processing flow. According to the method, the cough sound collection quality and the disease subtype recognition accuracy in a complex environment are improved, meanwhile, the thermodynamic diagram is output to assist clinical decision making, and the diagnosis credibility and practicability are enhanced.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

Apparatus and methods for deactivating bronchial nerves and ablating smooth muscle extending along a bronchial branch of a mammalian subject to treat asthma and related conditions. An ultrasonic transducer (11) is inserted into the bronchus as, for example, by advancing the distal end of a catheter (10) bearing the transducer into the bronchial section to be treated. The ultrasonic transducer emits ultrasound so as to heat tissues throughout a relatively large impact volume (13) to a temperature sufficient to inactivate nerve conduction and ablate smooth muscle but insufficient to cause rapid ablation or necrosis of the surrounding tissues. The treatment can be performed without locating or focusing on individual bronchial nerves or smooth muscle.

Described herein are antibodies that bind Interleukin 4 Receptor alpha (IL-4Rα) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-4Rα biological activity. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL-4 and / or IgE. In certain aspects, described herein are methods of treating asthma by administering anti-IL4Rα antibodies.

The present application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for relieving cough and asthma, and a preparation method and application thereof. The traditional Chinese medicine composition comprises, in mass parts, perilla seed 5-15 parts, radish seed 5-15 parts, white mulberry bark 5-15 parts, orange red or processed orange red 5-15 parts, and cassia 5-15 parts. The traditional Chinese medicine composition has the effect of relieving cough and asthma, can effectively improve the clinical symptoms such as cough, expectoration and wheezing of patients with chronic obstructive pulmonary disease, promote lung rehabilitation, improve the dyspnea condition of the patients, and improve the life quality of the patients.

Methods, devices and systems are described for decreasing the activity of the sympathetic nervous innervation to and from the lungs and the vessels supplying the lungs to treat pulmonary medical conditions such as asthma. In one embodiment, the method may involve advancing an intravascular instrument to a target location in a blood vessel within the intercostal vasculature to ablate either or both the sympathetic afferent and efferent nerves lying within the paravertebral gutter including the visceral fibers that travel to the cardiothoracic cavity and abdominopelvic viscera and the T1 to T4 / 5 sympathetic chain. In another embodiment, an intravascular instrument may be advanced to the bronchial vessels to ablate either or both the sympathetic afferent and efferent nerves in and around the posterior pulmonary plexus. In one embodiment the ablative agent is a neurolytic agent delivered in a gel. This approach may be utilized to treat other cardiac and pulmonary diseases.

The invention discloses an intelligent respiratory disease detection system based on lung function measurement indexes, and relates to the technical field of intelligent medical detection. The problems that diagnosis standards are not uniform and depend on experience, primary doctors are prone to missed diagnosis or misdiagnosis due to insufficient experience, and the efficiency of the detection process is low are solved. According to the method, a machine learning model is constructed based on lung function indexes, parameters are optimized through five-fold cross validation, automatic classification of asthma, COPD and ILD / DPLD is achieved, the overall diagnosis accuracy rate reaches 81.3%, the limitation that traditional diagnosis depends on doctor experience is broken through, and the basic medical diagnosis capacity is especially improved. Healthy people are rapidly eliminated through the FVC / FEV1 ratio, invalid calculation is reduced, meanwhile, multi-model weighted fusion is adopted for complex cases, diagnosis robustness is improved, it is ensured that diagnosis results conform to medical logic, the recognition degree of doctors is enhanced, a data basis is provided for clinical research and curative effect tracking, and respiratory disease diagnosis is promoted to develop towards the direction of automation and precision.

The invention provides a traditional Chinese medicine composition for relieving cough and asthma and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 5-15 parts of herba ardisiae japonicae, 5-15 parts of honey-fried folium eriobotryae, 1-3 parts of honey-fried herba ephedrae, 2-5 parts of semen armeniacae amarae, 1-5 parts of roselle, 2-6 parts of mint, 2-6 parts of pericarpium citri reticulatae, 2-6 parts of caulis bambusae in taeniam, 4-12 parts of herba houttuyniae and 1-3 parts of honey-fried licorice root. The herba ephedrae is changed into the honey herba ephedrae, and the roselle is added, so that the product is weakened in sweating effect and more prominent in lung moistening and cough relieving, and is more suitable for weak people to use, and the applicable crowd is widened; meanwhile, a hydrotropy technology is adopted in the production and use process, so that the solubility of traditional Chinese medicine components is improved; the traditional Chinese medicine composition is taken after being mixed with warm water, solves the problem of overhigh alcohol content in the original product, is convenient to carry and adjustable in administration dosage, and is convenient for children and patients to use.

The present invention provides a composition for use in the prevention and / or treatment of a viral infection in an individual wherein the composition comprises Bifidobacterium longum subsp. Infantis and a mixture of HMO consisting of 2 '-fucosyllactose (2FL), difucosyllactose (DFL), lactose-N-tetraose (LNT), 6'-sialyllactose (6SL), 3 '-sialyllactose (3SL), and 3-fucosyllactose (3FL). The present invention also provides compositions for use in preventing and / or reducing the risk of allergen sensitization, preventing and / or reducing the risk of developing respiratory disorders in an individual, and / or preventing and / or reducing the risk of developing asthma in an individual.

The present invention relates to a composition comprising a Bifidobacterium longum transitional microorganism and a mixture of human milk oligosaccharides (HMOs) consisting of 2'-fucosyllactose (2'-FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyllactose (6SL), and 3'-sialyllactose (3SL), and optionally lacto-N-fucopentaose I (LNFP-I), 3- fucosyllactose (3-FL) and / or lacto-N-neotetraose (LNnT), wherein the Bifidobacterium longum transitional microorganism has an Average Nucleotide Identity (ANI) of at least 98% with CNCM I-5942. The invention also relates to the use of the composition for preventing, reducing the risk of and / or treating an infection in a subject. The invention also provides the composition for use in promoting a long-term immune benefit in a subject, preventing and / or reducing the risk of allergen sensitisation, preventing and / or reducing the risk of developing a respiratory condition in a subject, and / or preventing and / or reducing the risk of developing asthma in a subject.

The invention relates to the technical field of biological medicine, in particular to a drug screening model construction method based on airway organs, a model and application. The construction method of the drug screening model of the airway organoid comprises the steps of obtaining 2D airway epithelial cells, culturing the airway organoid, establishing an airway organoid inflammation model and / or establishing an airway organoid mucus secretion / goblet cell metaplasia model. Wherein the model is established according to the culture mode of the airway organ in cooperation with a specific stimulant for proliferation and differentiation. Compared with a traditional animal model, the organ-like model is low in cost and short in construction period, can better simulate the pathological process, can realize airway organ-like culture and establishment of an inflammation model and a mucus secretion / goblet cell metaplasia model at the same time, and has a good application prospect in drug detection of asthma and COPD diseases.

The present invention relates to the use of an ROR inverse agonist or a pharmaceutically acceptable salt thereof for the preparation of a medicament for modulating ROR in a patient and / or for controlling autoimmune diseases and antibody-mediated rejection in a patient. The ROR-mediated diseases or autoimmune diseases include HIV, cancer, celiac disease, type 1 diabetes, Graves' disease (Graves' disease), inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease (Crohn's disease), cardiovascular disease, inflammatory disease, nervous system disorders, multiple sclerosis, and the like. Acute respiratory distress syndrome and arteriosclerosis.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating gastroesophageal reflux cough and a preparation method thereof. The traditional Chinese medicine composition disclosed by the invention is constructed by carefully selecting a medicine formula under the guidance of a traditional Chinese medicine theory and clinical experience and through a compatibility theory of monarch, minister, assistant and guide of traditional Chinese medicines. In the traditional Chinese medicine composition, the inula flower has the effects of promoting blood circulation, removing stasis and turbidity, clearing the airway and removing phlegm and fluid retention, and the mangnolia officinalis has the effects of promoting qi circulation, removing food retention, calming adverse-rising energy and relieving asthma, and both serve as monarch drugs; the dried orange peel has the effects of regulating qi and removing stagnation, the poria cocos has the effects of tonifying spleen, eliminating dampness and phlegm and breaking up the source of phlegm, and the bulbus fritillariae cirrhosae has the effects of clearing heat and moistening lung and resolving phlegm and relieving asthma; the rhizoma atractylodis macrocephalae has the effects of invigorating the spleen, replenishing qi, eliminating dampness and inducing diuresis, and the endothelium corneum gigeriae galli has the effects of promoting digestion and invigorating the stomach and is an assistant and guide drug. The whole prescription is ordered in monarch and minister, focuses on pathogenesis, is rigorous in prescription, has the effects of relieving cough and asthma, clearing heat and moistening lung, and strengthening spleen and stomach, and treats both symptoms and root causes of cough.

The application provides a galactoside agglutinin 10 (Gal10) crystal and a preparation method and prepared antibody IgY and a pharmaceutical preparation thereof, and belongs to the technical field of medicines. The application uses the galactoside agglutinin 10 crystal as an antigen to prepare an egg yolk neutralizing antibody IgY capable of dissolving the Gal10 crystal, has the effects of improving rhinitis or asthma of a patient, preventing and treating rhinitis and asthma, and is safe, has no side effects, has a long-lasting curative effect, and has no drug resistance, thereby providing a safe, simple, hygienic, effective, economic and personalized treatment mode for prevention and treatment of rhinitis and asthma, and having a high market value.

The invention discloses a preparation method of cough and asthma relieving granules, and belongs to the field of traditional Chinese medicine preparation, and the preparation method comprises the following steps: S1, sealed extraction to obtain a mixed solution: performing pulse type ultrasonic treatment on folium rhododendri daurici in an ethanol water solution for 1-3 minutes, then extracting for 66-78 hours at the temperature of 30-40 DEG C, and intermittently stirring; s2, filtering and squeezing to obtain an extracting solution; s3, concentrating the extracting solution to obtain a clear paste with the relative density of 1.10-1.2 at the temperature of 70-80 DEG C; s4, adjusting the pH value to 3.5-5.5, and removing astringency; s5, filtering with an ultrafiltration membrane, concentrating to obtain clear paste with the relative density of 1.10-1.2 at 70-80 DEG C, and spray-drying the clear paste to obtain extract powder; and S6, adding auxiliary materials into the extract powder, mixing, adjusting, preparing granules, drying, finishing the granules, screening, totally mixing, and sub-packaging to obtain the cough and asthma relieving granules. The extraction time is shortened, and the product stability is improved.

The invention discloses a preparation method and application of bioactive lipid and lipid nanoparticles thereof. The bioactive lipid molecule is formed by bonding long-chain fatty acid (LCFA) with different chain lengths with two functional small molecules, namely phenylboronic acid pinacol ester (PBAP) and Tempol (Tpl) respectively, so that two types of lipid molecules, namely PBAP-LCFA and Tpl-LCFA, with anti-inflammatory activity are constructed. The lipids are used as functional components, and the anti-inflammatory lipid nanoparticles with good biocompatibility, including PLP, TLP and TPLP, can be prepared through a film dispersion method. The lipidoid and the lipid nanoparticles are simple and convenient in preparation process, controllable in structure and function and easy for large-scale production, and have treatment potential in various acute and chronic inflammatory diseases. In an animal model, the lipid nanoparticles have remarkable curative effects on acute peritonitis, acute lung injury, acute hepatic failure, asthma and other diseases. Besides, the lipid bilayer structure of the TPLP can efficiently entrap hydrophilic / hydrophobic drugs, can synergistically deliver treatment drugs while exerting the anti-inflammatory effect of the TPLP, and realizes a synergistic combined treatment strategy for chronic lung inflammation and other diseases.

The invention discloses a back cumin treatment method which is used for relieving symptoms of patients with chronic obstructive pulmonary disease and chronic bronchitis. The method comprises the following steps: preparing a cumin ground medicine which comprises 9g of viola tianshanica, 9g of hollyhock seed, 9g of common fenugreek seed, 9g of dill seed, 9g of linseed, 9g of chamomile, 100g of sesame oil or olive oil and other materials, blending the medicine and oil or warm boiled water into a paste at 38-40 DEG C, applying the paste to lung positions (15 * 20cm, 0.3-0.5 cm in thickness) on two sides of the back of a patient, covering the lung positions with a preservative film, irradiating the lung positions with a TDP baking lamp which is not less than 20cm in height for 20-30 minutes, and cleaning the medicine applying positions after the process is finished. Viola tianshanica in the cumin geomedicine can clear away heat and toxic materials, diminish inflammation and relieve pain, hollyhock seeds can clear heat and induce diuresis, and relieve cough and asthma, through the treatment, the medicine efficiently permeates and quickly acts on diseased regions, the symptoms of patients are effectively relieved, and the life quality is improved.

The invention discloses a traditional Chinese medicine composition for treating cough. The invention belongs to the field of traditional Chinese medicine for treating cough. The traditional Chinese medicine composition is prepared from 17 traditional Chinese medicines including thunberg fritillary bulb, semen lepidii, platycodon grandiflorum, perilla leaf, almond, polygala tenuifolia, schisandra chinensis and the like. The cough is not injured by lung and cough, not injured by spleen and not coughed for a long time, and not injured by kidney and not cough and asthma, and the cough is not cured for a long time and is mostly caused by lung yin deficiency and kidney deficiency. Years of research finds that the fundamental cause of cough is lung qi upflow and phlegm obstructing lung regardless of external infection, internal injury and deficiency and excess symptoms, and the basic thought of treatment is to reduce phlegm and expel fluid retention; the lung qi is reduced; and tonifying spleen and kidney. According to the theory, the traditional Chinese medicines are screened according to the principle of syndrome differentiation and treatment of traditional Chinese medicine, and the prescription is an empirical prescription which is continuously explored and gradually formed in the practice process. The traditional Chinese medicine composition has a treatment effect on cough.

The present disclosure relates to an orthogonal system comprising a first bi-specific polypeptide that comprises D-streptavidin or a variant thereof covalently linked to an antibody or antibody fragment and a second bi-specific polypeptide that comprises L-biotin covalently linked to a therapeutic or diagnostic agent. The disclosed systems can be useful in, for example, treating a disease or a condition (e.g., cancer, non-Hodgkin lymphoma, multiple sclerosis, Crohn's disease, rheumatoid arthritis, asthma, macular degeneration, psoriasis, Hodgkin lymphoma, paroxysmal nocturnal hemoglobinuria, X-linked hypophosphatemia). Also described are peptides and polypeptides useful in preparing the disclosed bi-specific polypeptides and methods of making same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

The present disclosure relates to compounds of Formula I and pharmaceutically acceptable salts thereof, wherein X, R1-R4, n and m have the meanings given in the specification. The compounds of formula I exhibit GPR183 antagonistic activity and are therefore useful in the treatment or prevention of disorders, conditions or diseases to which GRP183 antagonists are applicable, such as chronic pain, such as osteoarthritis, chronic lumbago, neuropathic pain, and immune system diseases, such as inflammatory bowel diseases, such as colitis and Crohn's disease, multiple sclerosis, rheumatoid arthritis, inflammatory lung diseases, and the like. , such as asthma and psoriasis.

Provided are substituted 8-methylquinazolin-4(3H)-one compounds useful as PARP inhibitors for the treatment of cancer and asthma, as well as pharmaceutical compositions comprising them and methods for their synthesis.

The invention discloses a detection method of a blood entering component of a Mongolian medicine Tiangu-3 for treating asthma, and relates to the technical field of medicine in-vivo metabolism, and the detection method specifically comprises the following steps: S1, collection of a biological sample: respectively collecting initial blank serum and drug-containing serum for later use; s2, preparation of a biological sample: treating the initial blank serum and the drug-containing serum to obtain blank serum and drug administration serum samples for later use; s3, preparing an in-vitro test sample, namely treating daily check-3 to obtain a traditional Chinese medicine sample for later use; and S4, respectively taking the blank serum, the administration serum and 10 mu L of the traditional Chinese medicine sample, carrying out LC-MS / MS analysis, and determining the in-blood components based on the detection result. The method disclosed by the invention can more comprehensively reveal the characteristics of the drug-derived components after the drug enters the blood, and fills the blank in the fields of qualitative analysis of the components entering the blood and quantitative detection of all the effective components in the Jiaogue-3 (Jiaogue-3) (Jiaogue-3) (Jiaogue-3).

The invention discloses an application of isothunberine or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and / or treating asthma diseases. It is found that in an OVA-induced mouse asthma model, the isothunberine significantly reduces airway resistance excited by acetylcholine, improves inflammatory cell infiltration and airway mucus high secretion of asthma model mouse lung tissue, reduces the levels of lgE and OVA-lgE in serum and related inflammatory factors in alveolar lavage fluid, and has the effect of preventing and treating asthma. Therefore, the effect of treating asthma is achieved. Therefore, the isothunberine has the potential of preventing or treating the asthma, provides a new treatment mode for the treatment of the asthma, and has a wide application prospect.

The present invention provides novel drug-linker conjugates and antibody-drug conjugates of imidazo quinoline amine derivatives, which have agonistic activity against Toll-like receptors (TLRs), in particular TLR7 and / or TLR8, also provided are pharmaceutical compositions and methods of treatment against certain diseases or conditions mediated by or associated with TLR7 and / or TLR8 (e.g., graft rejection, autoimmunity, inflammation, allergy, asthma, infection, sepsis, cancer, and immunodeficiency).

The present disclosure provides interactive education systems, apparatus, components, and methods for teaching patient care. In some instances, devices, systems, and associated methods include air trapping techniques for asthma simulation. In some aspects of the present disclosure, a system comprises: a patient simulator having a simulated body portion; and an asthma simulation module positioned within the simulated body portion, the asthma simulation module including: a first simulated lung; an adjustable valve along a first air path between a simulated trachea and the first simulated lung; and an air trapping module along a second air path between the simulated trachea and the first simulated lung.

The present invention discloses a traditional Chinese medicine composition for treating chronic bronchitis combined with emphysema. The composition is prepared by extracting the following traditional Chinese medicine raw materials in parts by weight: 20-30 parts of ginseng, 15-25 parts of astragalus, 20-30 parts of prepared rehmannia, 18-22 parts of schisandra, 15-25 parts of pinellia, and 20-30 parts of poria. The composition nourishes the liver, spleen, and kidneys, reduces stomach qi, purges the lungs, and relieves asthma, promotes diuresis and reduces swelling, promotes blood circulation and removes blood stasis, regulates qi and resolves phlegm, and is suitable for treating chronic bronchitis combined with emphysema. The present invention also discloses a preparation method and use thereof.